CE3F4

CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC50s of 10.7 μM and 66 μM for Epac1 and Epac2 (B), respectively.

Product Specifications

CAS Number

[143703-25-7]

UNSPSC

12352005

Hazard Statement

H302, H411

Target

Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/CE3F4.html

Purity

98.85

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=CN1C(C)CCC2=C1C=C(Br)C(F)=C2Br

Molecular Formula

C11H10Br2FNO

Molecular Weight

351.01

Precautions

H302, H411

References & Citations

[1]Courilleau D, et al. The (R) -enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1) . Biochem Biophys Res Commun. 2013 Oct 25;440 (3) :443-8.|[2]Courilleau D, et al. Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J Biol Chem. 2012 Dec 28;287 (53) :44192-202.|[3]Pratt EP, et al. Ca2+ influx through L-type Ca2+ channels and Ca2+-induced Ca2+ release regulate cAMP accumulation and Epac1-dependent ERK 1/2 activation in INS-1 cells. Mol Cell Endocrinol. 2016 Jan 5;419:60-71.|[4]Prajapati R, et al. Usefulness of Exchanged Protein Directly Activated by cAMP (Epac) 1-Inhibiting Therapy for Prevention of Atrial and Ventricular Arrhythmias in Mice. Circ J. 2019;83 (2) :295-303.|[5]Abstract 17548: Inhibition of Exchange Protein 1 Directly Activated by cAMP (Epac1) is Cardioprotective Against Ischemia-reperfusion Injury